|
Collaborative Arrangements (Details Textual 1) (USD $)
In Millions, unless otherwise specified |
9 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
Takeda Pharmaceutical Company Limited [Member]
|
Jun. 29, 2012
Takeda Pharmaceutical Company Limited [Member]
|
Dec. 31, 2008
Takeda Pharmaceutical Company Limited [Member]
Japanese market products [Member]
Molecule
|
Sep. 30, 2012
Takeda Pharmaceutical Company Limited [Member]
Other revenues [Member]
|
Jun. 30, 2012
Takeda Pharmaceutical Company Limited [Member]
Other revenues [Member]
|
Dec. 31, 2008
Takeda Pharmaceutical Company Limited [Member]
Milestone payments deferred or capitalized [Member]
|
Jun. 30, 2012
License arrangement for Motesanib with Takeda Pharmaceutical Company Limited [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||
| Number of molecules developed and commercialized as per collaborations | 12 | ||||||
| Milestone payment received | $ 300 | ||||||
| Amortization period of payments received and deferred under collaborative arrangements, in years | 20 years | ||||||
| Deferred revenue as of the date of modification of the original arrangement | 230 | ||||||
| Milestone payments received under arrangements | 3 | ||||||
| Incremental cost to be recovered | 21 | ||||||
| Revenue previously deferred recognized as a result of a material modification to the agreement | 24 | 206 | |||||
| Payments that may be received upon the achievement of various substantive success-based development and regulatory approval milestones | $ 337 | ||||||